Is it time to take profits on GlaxoSmithKline plc and AstraZeneca plc?

After recent gains is it time to sell GlaxoSmithKline plc (LON: GSK) and AstraZeneca plc (LON: AZN)?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Since Brexit, the FTSE 100 has been on a staggering run gaining 10.8% as sterling has slumped. This sterling weakness has helped make the index more attractive to overseas buyers and pushed up the earnings of those companies that have operations overseas but report profits in GBP.

AstraZeneca (LSE: AZN) and GlaxoSmithKline (LSE: GSK) are two companies that have benefitted from this trend. Indeed, since Brexit shares in Astra have gained a staggering 32% and Glaxo’s shares have gained 19.4%, both outperforming the wider FTSE 100 by a wide margin.

But is it time to sell? Recent gains have taken the share price of Astra to a multi-year high despite the company’s deteriorating operating performance. It’s still unclear how Astra will fare after 2016 as the company loses the exclusive manufacturing rights to its blockbuster Crestor treatment.

Should you invest £1,000 in BP right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if BP made the list?

See the 6 stocks

A Crestor cliff

Crestor was Astra’s best-selling drug, raking in more than $4bn per annum for the group at its peak. However, this year the substance patent for it expires, which means that Astra loses the exclusive manufacturing rights to the product. The patent was set to expire at the beginning of January, but AstraZeneca won a six-month extension under the US paediatric trials incentive programme. The extension officially expired on 8 July, a week after the end of Astra’s Q2.

For the first half of 2016 Astra reported a 17% decline in core operating profit and a 22% decline in core earnings per share and it’s likely these declines will only accelerate as Crestor comes off patent. The company has been trying to replace its revenue with new treatments, but these have been slow to come to market.

Still, Astra should receive a boost from sterling’s devaluation. Within the company’s first-half results release, management stated: “Core EPS is now expected to benefit from currency movements by a low to mid-single-digit percentage versus the prior year.” Although it remains to be seen if this currency boost will be enough to offset the revenue losses from Crestor coming off patent. 

City analysts expect Astra to report a 7% decline in EPS for 2016. Based on these forecasts the company is trading at a forward P/E of 16.6 and the shares support a dividend yield of 4.1%.

A better pick

Astra struggles but Glaxo seems to be charging ahead as the company’s multi-year transformation plan starts to pay off. 

At the end of July, it reported core sterling EPS growth of 28% for the first half of 2016, with core sterling operating profit up a staggering 36% year-on-year for Q2. Sales increased across all of the company’s reported business divisions with group sales for the period growing by 4% at constant exchange rates to £6.5bn. Sterling’s devaluation is responsible for most of this growth. Within Glaxo’s first-half results release management noted that the estimated impact of post-Brexit sterling weakness is a 19% boost to core EPS. 

Nonetheless, underlying revenue growth for the first half shows that Glaxo is making steady progress in growing sales and isn’t just relying on accounting treatments to boost income.

Analysts expect Glaxo to report EPS growth of 27% for 2016. Based on these forecasts the company trades at a forward P/E of 17.4 and the shares support a dividend yield of 4.9%.

In my opinion, based on Glaxo and Astra’s current growth outlook, it looks as if it might make sense to consider booking profits in Astra but holding on to Glaxo. 

But this isn’t the only opportunity that’s caught my attention this week. Here are:

5 Shares for the Future of Energy

Investors who don’t own energy shares need to see this now.

Because Mark Rogers — The Motley Fool UK’s Director of Investing — sees 2 key reasons why energy is set to soar.

While sanctions slam Russian supplies, nations are also racing to achieve net zero emissions, he says. Mark believes 5 companies in particular are poised for spectacular profits.

Open this new report5 Shares for the Future of Energy — and discover:

  • Britain’s Energy Fort Knox, now controlling 30% of UK energy storage
  • How to potentially get paid by the weather
  • Electric Vehicles’ secret backdoor opportunity
  • One dead simple stock for the new nuclear boom

Click the button below to find out how you can get your hands on the full report now, and as a thank you for your interest, we’ll send you one of the five picks — absolutely free!

Grab your FREE Energy recommendation now

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns shares of GlaxoSmithKline. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Shot of a senior man drinking coffee and looking thoughtfully out of a window
Investing Articles

I’m trying to follow Warren Buffett’s advice with this FTSE 100 stock

As Warren Buffett steps aside at Berkshire Hathaway, Stephen Wright is thinking about how to put his investing principles into…

Read more »

Portrait Of Senior Couple Climbing Hill On Hike Through Countryside In Lake District UK Together
Investing Articles

I bought 3,254 Taylor Wimpey shares 2 years ago – here’s how much income they’ve paid since

Harvey Jones says his investment in Taylor Wimpey shares hasn't delivered much growth so far but the dividends are now…

Read more »

Road 2025 to 2032 new year direction concept
Investing Articles

Here’s why I started a pension (SIPP) for my 1-year-old

The SIPP gives Britons more control over their pensions. Dr James Fox explains why parents should consider opening SIPPs for…

Read more »

Close-up of a woman holding modern polymer ten, twenty and fifty pound notes.
Investing Articles

£20K of savings? Here’s how it could fuel a £633 monthly second income

Christopher Ruane outlines some practical steps a stock market newbie could take to building a sizeable second income from dividend…

Read more »

Young mixed-race woman jumping for joy in a park with confetti falling around her
Investing Articles

2 shares to consider as a new US deal could revive the UK stock market

Our writer investigates two major FTSE 100 shares that could enjoy a boost following a US tariff shift and possible…

Read more »

Happy young female stock-picker in a cafe
Investing Articles

This FTSE 250 growth trust just loaded up on these 2 top S&P 500 stocks

Our writer noticed that this FTSE 250 investment trust has just scooped up a couple of quality US growth stocks.…

Read more »

British flag, Big Ben, Houses of Parliament and British flag composition
Investing Articles

This world-class FTSE 100 company’s expecting up to 10% growth in 2025

This is one of the most profitable companies in the FTSE 100 index. And right now, it’s firing on all…

Read more »

Surprised Black girl holding teddy bear toy on Christmas
Investing Articles

£10k invested in Phoenix shares 10 years ago would have generated passive income of…  

Shares in this FTSE 100 insurance giant have done poorly over the last decade. Harvey Jones wonders if super-sized passive…

Read more »